Inhibition of Arterial Thrombosis by a Soluble Tissue Factor Mutant and Active Site-blocked Factors IXa and Xa in the Guinea Pig

Summary

The substrate recognition region of tissue factor contains two residues, Lys165 and Lys166, which are important for macromolecular substrate activation by the tissue factor:factor VIIa complex. Replacement of these two residues with alanine in a soluble version of human tissue factor resulted in a mutant, hTFAA, which can bind factor VIIa but forms an enzymatically inactive complex. We found that hTFAA inhibits the activity of guinea pig factor VIIa, allowing us to evaluate hTFAAs effects on thrombosis and hemostasis in a guinea pig model of recurrent arterial thrombosis. In addition to heparin, the effects of hTFAA were compared to active site inhibited factor IXa (F.IXai) and factor Xa (F.Xai). We found that hTFAA, F.IXai and F.Xai were potent antithrombotics and may possess a decreased risk of hemorrhage when compared to unfractionated heparin. When administered at a dose that inhibited thrombosis by about 90%, hTFAA neither affected cuticle bleeding nor the activated partial thromboplastin time, and had only a modest effect on the prothrombin time. At equi-efficacious doses, F.IXai, F.Xai and heparin prolonged bleeding times by 20% (p >0.5), 50% (p <0.05) and 100% (p <0.01), respectively. In summary, our study demonstrates that, unlike heparin, specific inhibitors of factors VIIa, IXa and Xa can produce antithrombotic effects without or with only minimally disturbing normal hemostasis. The results further suggest that factor VIIa and factor IXa are especially promising targets for antithrombotic drug development.

Keywords

Tissue factor - factor IX - factor X - factor VII - anticoagulants - thrombosis

^* Current address: Actelion Ltd., Allschwil, Switzerland

^** Current address: Department of Cardiovascular Research, Genentech Inc., South San Francisco, USA

• References

• 1 Nemerson Y. The tissue factor pathway of blood coagulation. Sem Hematol 1992: 170-6.
• 2 Edgington TS, Dickinson CD, Ruf W. The structural basis of function of the TF·VIIa complex in the cellular initiation of coagulation. Thromb Haemost 1997; 78: 401-5.
• 3 Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-43.
• 4 Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995; 74: 1-6.
• 5 Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 165-74.
• 6 Annex BH, Denning SM, Channon KM, Sketch Jr MH, Stack RS, Morrissey JH, Peters KG. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995; 91: 619-22.
• 7 Moreno PR, Bernardi VH, Lopez-Cuellar J, Murcia AM, Palacios IF, Gold HK, Mehran R, Sharma SK, Nemerson Y, Fuster V, Fallon JT. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Circulation 1996; 94: 3090-7.
• 8 Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, Fallon JT, Nemerson Y, Taubmann MB. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94: 1226-32.
• 9 Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thromobogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-9.
• 10 Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques. Circulation 1999; 99: 1780-7.
• 11 Semeraro N, Colucci M. Tissue factor in health and disease. Thromb Haemost 1997; 78: 759-64.
• 12 Kirchhofer D, Lipari MT, Moran P, Eigenbrot C, Kelley RF. The tissue factor region that interacts with substrates factor IX and factor X. Biochemistry 2000; 39: 7380-7.
• 13 Ruf W, Miles DJ, Rehemtulla A, Edgington TS. Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor VIIa protease complex. J Biol Chem 1992; 267: 6375-81.
• 14 Ruf W, Miles DJ, Rehemtulla A, Edgington TS. Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII. J Biol Chem 1992; 267: 22206-10.
• 15 Roy S, Hass PE, Bourell JH, Henzel WJ, Vehar GA. Lysine residues 165 and 166 are essential for the cofactor function of tissue factor. J Biol Chem 1991; 266: 22063-6.
• 16 Huang Q, Neuenschwander PF, Rezaie AR, Morrissey JH. Substrate recognition by tissue factor-factor VIIa. Evidence for interaction of residues Lys165 and Lys166 of tissue factor with the 4-carboxyglutamate-rich domain of factor X. J Biol Chem 1996; 271: 21752-7.
• 17 Dittmar S, Ruf W, Edgington TS. Influence of mutations in tissue factor on the fine specificity of macromolecular substrate activation. Biochem J 1997; 321: 787-93.
• 18 Kelley RF, Refino CJ, O’Connell MP, Modi N, Sehl P, Lowe D, Pater C, Bunting S. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood 1997; 89: 3219-27.
• 19 Vlasuk GP, Ramjit D, Fujita T, Dunwiddie CT, Nutt EM, Smith DE, Shebuski RJ. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost 1991; 65: 257-62.
• 20 Benedict CR, Ryan J, Wolitzky B, Ramos R, Gerlach M, Tijburg P, Stern D. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest 1991; 88: 1760-5.
• 21 Benedict CR, Ryan J, Todd J, Kuwabara K, Tijburg P, Cartwright Jr J, Stern D. Active site-blocked factor Xa prevents thrombus formation in the coronary vasculature in parallel with inhibition of extravascular coagulation in a canine thrombosis model. Blood 1993; 81: 2059-66.
• 22 Fioravanti C, Burkholder D, Francis B, Siegl PKS, Gibson RE. Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis. Thromb Res 1993; 71: 317-24.
• 23 Lefkovits J, Malycky JL, Rao JS, Hart CE, Plow EF, Topol EJ, Nicolini FA. Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model. J Am Coll Cardiol 1996; 28: 1858-65.
• 24 Rebello SS, Blank HS, Rote WE, Vlasuk GP, Lucchesi BR. Antithrombotic efficacy of recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration. J Pharmacol Exp Therap 1997; 283: 91-9.
• 25 Wong AG, Gunn AC, Ku P, Hollenbach SJ, Sinha U. Relative efficacy of active site-blocked factors IXa, Xa in models of rabbit venous and arteriovenous thrombosis. Thromb Haemost 1997; 77: 1143-7.
• 26 Morishima Y, Tanabe K, Terada Y, Hara T, Kunitada S. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: Comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost 1997; 78: 1366-71.
• 27 Sato K, Kawasaki T, Hisamichi N, Taniuchi Y, Hirayama F, Koshio H, Matsumoto Y. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. Brit J, Pharmacol 1998; 123: 92-6.
• 28 Spanier TB, Oz MC, Minanov OP, Simantov R, Kisiel W, Stern DM, Rose EA, Schmidt AM. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study in the dog. J Thorac Cardiovasc Surg 1998; 115: 1179-88.
• 29 Feuerstein GZ, Patel A, Toomey JR, Bugelski P, Nichols AJ, Church WR, Valocik R, Koster P, Baker A, Blackburn MN. Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. Arterioscler Thromb Vasc Biol 1999; 19: 2554-62.
• 30 Refino CJ, Himber J, Burcklen L, Moran P, Peek M, Suggett S, Devaux B, Kirchhofer D. A human antibody that binds to the γ-carboxyglutamic acid domain of factor IX is a potent antithrombotic in vivo. Thromb Haemost 1999; 82: 1188-95.
• 31 Heran C, Morgan S, Kasiewski C, Bostwick J, Bentley R, Klein S, Chu V, Brown K, Colussi D, Czekaj M, Perrone M, Leadley Jr R. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis. Eur J, Pharmacol 2000; 389: 201-7.
• 32 Roux S, Carteaux JP, Hess P, Falivene L, Clozel JP. Experimental carotid thrombosis in the guinea pig. Thromb Haemost 1994; 71: 252-6.
• 33 Carteaux JP, Gast A, Tschopp TB, Roux S. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circulation 1995; 91: 1568-74.
• 34 Kirchhofer D, Tschopp TB, Baumgartner HR. Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model. Arterioscler Thromb Vasc Biol 1995; 15: 1098-106.
• 35 Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58: 1078-84.
• 36 Pawashe AB, Golino P, Ambrosio G, Migliaccio F, Ragni M, Pascucci I, Chiariello M, Bach R, Garen A, Konigsberg WK, Ezekowitz MD. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994; 74: 56-63.
• 37 Shi R-J, Li W-Z, Marder VJ, Sporn LA. Cloning of guinea pig tissue factor cDNA: comparison of primary structure among six mammalian species. Thromb Haemost 2000; 83: 455-61.
• 38 Chang Y-J, Hamaguchi N, Chang S-C, Ruf W, Shen M-C, Lin S-W. Engineered recombinant factor VII Q217 variants with altered inhibitor specificities. Biochemistry 1999; 38: 10940-8.
• 39 Broze Jr GJ. Binding of human factor VII and VIIa to monocytes. J Clin Invest 1982; 70: 526-35.
• 40 Zur M, Radcliffe RD, Oberdick J, Nemerson Y. The dual role of factor VII in blood coagulation. J Biol Chem 1982; 257: 5623-31.
• 41 Vlasuk GP, Bergum PW, Rote WE, Ruf W. Mechanistic and pharmacological evaluation of NAPc2, a novel small protein inhibitor of the factor VIIa/ tissue factor complex. Thromb Haemost 1997; Suppl. 688 (abstract #PS-2807).
• 42 Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D, Wilcox JN. Anti-thrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis. Arterioscler Thromb 1992; 12: 948-54.
• 43 Himber J, Kirchhofer D, Riederer M, Tschopp TB, Steiner B, Roux SP. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost 1997; 78: 1142-9.
• 44 De Guzman L, Refino CJ, Steinmetz H, Bullens S, Lipari T, Smyth R, Eaton D, Bunting S. Inhibition of tissue factor or intrinsic Xase are effective antithrombotic strategies in a new model of venous thrombosis. Thromb Haemost 1997; Suppl. 292 (abstract #PS-1194).
• 45 Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithrombotic and anti-lesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis 1996; 26 (Suppl. 01) 76-82.
• 46 Golino P, Ragni M, Cirillo P, D’Andrea D, Scognamiglio A, Ravera A, Buono C, Ezban M, Corcione N, Vigorito F, Condorelli M, Chiariello M. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis. Circ Res 1998; 82: 39-46.
• 47 Holst J, Kristensen AT, Kristensen HI, Ezban M, Hedner U. Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model. Eur J, Vasc Endovasc Surg 1998; 15: 515-20.
• 48 Feuerstein GZ, Toomey JR, Valocik R, Koster P, Patel A, Blackburn MN. An inhibitory anti-factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis. Thromb Haemost 1999; 82: 1443-5.
• 49 Suggett S, Kirchhofer D, Hass P, Lipari T, Moran P, Nagel M, Judice K, Schroeder K, Tom J, Lowman H, Adams C, Eaton D, Devaux B. Use of phage display for the generation of human antibodies that neutralize factor IXa function. Blood Coag Fibrinol 2000; 11: 27-42.
• 50 Ahmad SS, Rawala-Sheikh R, Walsh PN. Platelet receptor occupancy with factor IXa promotes factor X activation. J Biol Chem 1989; 264: 20012-6.
• 51 Sheth SB, Wilson D, Davis HM, Jorkasky D. Administration of a humanized monoclonal antibody to factor IX in healthy volunteers. Blood 1998; 92: 3629 (abstract #1491).
• 52 Erhardtsen E, Thomsen MS, Johannesen M, Falch JF, Bech RM. Inactivated factor VII, a new antithrombotic treatment: results from healthy volunteers. Thromb Haemost 1999; Suppl. 11 (abstract #32).